Wall Street Zen downgrades Novocure stock to Hold

Published on 10/13/2026 at 05:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue reached USD 184.00 million, up 16.00 percent year over year. MarketBeat set a USD 21.20 target for Novocure stock on October 10, 2026.

Key points in brief

Wall Street Zen downgraded Novocure from Buy to Hold on October 10, 2026.
Novocure reported USD 184.00 million in second-quarter 2026 revenue, up 16.00 percent year over year.
The company raised full-year 2026 revenue guidance to USD 710.00 million to USD 725.00 million.
Novocure is scheduled to report third-quarter 2026 results on October 29, 2026.

NVCR, JE00BYSS4X48, Illustration mit AI erstellt.

Wall Street Zen downgraded Novocure stock from Buy to Hold in a report dated October 10, 2026, according to MarketBeat. The report also cited a consensus target of USD 21.20 and a consensus rating of Hold.

Three milestones shape the story

On July 23, 2026, Novocure reported second-quarter revenue of USD 184.00 million, up 16.00 percent year over year, and adjusted EBITDA of USD 11.00 million versus a USD 10.00 million loss in the year-earlier quarter, according to Yahoo Finance.

In February 2026, the U.S. Food and Drug Administration approved Optune Pax for locally advanced pancreatic cancer, while Novocure reported 285 Optune Pax patients on therapy as of June 30, 2026, in the same earnings-call transcript. On October 1, 2026, Japan approved Optune Pax for adults with unresectable, locally advanced pancreatic cancer, according to Novocure.

What does the guidance raise mean?

Novocure raised full-year 2026 revenue guidance to USD 710.00 million to USD 725.00 million from USD 690.00 million to USD 710.00 million. The company also guided to adjusted EBITDA of USD 0.00 million to USD 15.00 million, with second-quarter gross margin at 78.00 percent versus 74.00 percent in the second quarter of 2025, according to Yahoo Finance. The margin comparison included a USD 5.00 million tariff refund, which makes the underlying improvement more important to monitor.

The operating data show why the rating debate remains balanced. Optune Gio had 4,636 active patients at June 30, 2026, an increase of 11.00 percent year over year, while Optune Pax contributed USD 1.60 million of second-quarter revenue. Japan adds a regulatory milestone, but reimbursement and site contracting remain important commercial execution variables.

Results date sets the next checkpoint

Novocure is scheduled to report third-quarter 2026 results on October 29, 2026, at 8:00 a.m. EDT, according to the company's investor-relations calendar. The next disclosed event is the third-quarter earnings conference call on the same date.

Market value and investor context

As of October 12, 2026, Novocure had a market capitalization of USD 1.7 billion and a 52-week range of USD 9.82 to USD 21.45. Those figures frame the Hold consensus alongside the company's revenue growth and expanding product portfolio.

The further course of trading is shown by the continuously updated real-time quote of Novocure stock.